Breast Cancer Foundation NZ
PERKing up immunotherapy in breast cancer
July 2019
Research Grant
What is the problem and who is affected?
The new immunotherapy drugs that have worked so well in cancers like melanoma are so far not helping much in breast cancer.
What is this research hoping to achieve?
A protein in the body called PERK may play a part in stopping immunotherapies from working in advanced breast cancer. Dr Dean Singleton at the University of Auckland will investigate whether suppressing PERK can improve immune responses in models of breast cancer, and whether an anti-PERK drug could be delivered directly to a breast tumour, where it could enable immunotherapy drugs to work.
-
OctoberResearch Grant
Using deep learning and digital pathology for detailed breast tumour analysis
-
OctoberResearch Grant
Validation of a liquid biopsy to predict recurrence in NZ breast cancer patients
-
OctoberResearch Grant
Predicting whether patients with HER2+ advanced breast cancer will respond to the drug Kadcyla
-
JulyResearch Grant
The Breast Atlas Project
-
JulyResearch Grant
Cancer EV catch-and-release – a new way of monitoring treatment effectiveness
-
JulyResearch Grant
PERKing up immunotherapy in breast cancer